ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07175
-0,05%
Bitcoin
66.264,48
0,39%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Celldex Therapeutics Inc (CLDX)

  7. Celldex Therapeutics Inc (CLDX) News

CLDX

Celldex Therapeutics (CLDX)

Celldex Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CLDX
DatumZeitQuelleÜberschriftSymbolFirma
14/06/202423h34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
14/06/202423h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
14/06/202422h02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CLDXCelldex Therapeutics Inc
14/06/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
13/06/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
11/06/202422h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
11/06/202422h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
07/06/202423h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
07/06/202422h57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
07/06/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
05/06/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
05/06/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
05/06/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
04/06/202422h01GlobeNewswire Inc.Celldex Therapeutics to Present at Jefferies Healthcare ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
03/06/202423h51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
03/06/202423h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
03/06/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
03/06/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
03/06/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
03/06/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
02/06/202415h01GlobeNewswire Inc.Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024NASDAQ:CLDXCelldex Therapeutics Inc
31/05/202400h05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
31/05/202400h01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
30/05/202423h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
30/05/202421h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
15/05/202414h01GlobeNewswire Inc.Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo NodularisNASDAQ:CLDXCelldex Therapeutics Inc
06/05/202422h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CLDXCelldex Therapeutics Inc
06/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
06/05/202422h01GlobeNewswire Inc.Celldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
17/04/202414h01GlobeNewswire Inc.Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CLDX

Kürzlich von Ihnen besucht

NYSE
DIS
Walt Disney
COIN
BTCUSD
Bitcoin
DBI
TDXP
Tec DAX
NYSE
NKE
Nike
PM
XAUUSD
Gold vs US Dollar
TG
432
Arbor Metals
NYSE
MCD
McDonalds
TG
CBK
Commerzbank
USOTC
BNPQY
BNP Paribas (QX)
NYSE
JPM
JP Morgan Chase
USOTC
BASFY
BASF (QX)
TG
BAS
BASF
TG
MBG
MercedesBenz
AMEX
XLV
Health Care Select Sector
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten